Simulations Plus, Inc. (NASDAQ:SLP) Shares Acquired by Barclays PLC

Barclays PLC grew its stake in Simulations Plus, Inc. (NASDAQ:SLP) by 390.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,473 shares of the technology company’s stock after buying an additional 22,669 shares during the period. Barclays PLC’s holdings in Simulations Plus were worth $911,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Deerfield Management Company L.P. Series C acquired a new position in shares of Simulations Plus in the 2nd quarter valued at $811,000. State Street Corp boosted its holdings in shares of Simulations Plus by 4.7% in the 3rd quarter. State Street Corp now owns 640,303 shares of the technology company’s stock valued at $20,503,000 after buying an additional 28,953 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Simulations Plus by 402.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 39,944 shares of the technology company’s stock valued at $1,279,000 after buying an additional 32,002 shares in the last quarter. Royce & Associates LP raised its position in Simulations Plus by 28.8% in the 3rd quarter. Royce & Associates LP now owns 237,416 shares of the technology company’s stock valued at $7,602,000 after purchasing an additional 53,092 shares during the last quarter. Finally, US Bancorp DE raised its position in Simulations Plus by 37.0% in the 3rd quarter. US Bancorp DE now owns 4,974 shares of the technology company’s stock valued at $159,000 after purchasing an additional 1,343 shares during the last quarter. Institutional investors and hedge funds own 78.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. BTIG Research reduced their price target on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. Stephens assumed coverage on shares of Simulations Plus in a research report on Friday, November 15th. They issued an “overweight” rating and a $39.00 price target for the company. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a research report on Wednesday, November 6th. Finally, StockNews.com downgraded shares of Simulations Plus from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. One analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Simulations Plus currently has an average rating of “Moderate Buy” and a consensus target price of $51.40.

Insider Activity

In other news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $27.66, for a total value of $553,200.00. Following the completion of the transaction, the director now owns 3,462,584 shares in the company, valued at $95,775,073.44. This trade represents a 0.57 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 20.90% of the company’s stock.

Simulations Plus Stock Performance

Shares of Simulations Plus stock opened at $27.94 on Tuesday. The company has a market cap of $561.17 million, a P/E ratio of 57.02 and a beta of 0.76. Simulations Plus, Inc. has a one year low of $27.07 and a one year high of $51.22. The firm has a fifty day moving average of $30.17 and a two-hundred day moving average of $34.82.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings data on Wednesday, October 23rd. The technology company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The company had revenue of $18.70 million during the quarter, compared to the consensus estimate of $19.73 million. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. Simulations Plus’s quarterly revenue was up 19.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.18 EPS. As a group, equities analysts predict that Simulations Plus, Inc. will post 1.1 earnings per share for the current year.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.